IPN N logo

Ipsen BMV:IPN N Stock Report

Last Price

Mex$1.94k

Market Cap

Mex$177.1b

7D

0%

1Y

n/a

Updated

14 Jul, 2024

Data

Company Financials +

IPN N Stock Overview

Operates as a biopharmaceutical company worldwide.

IPN N fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Ipsen S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ipsen
Historical stock prices
Current Share Price€1,936.56
52 Week High€1,936.56
52 Week Low€1,936.56
Beta0.62
11 Month Change0%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO13.00%

Recent News & Updates

Recent updates

Shareholder Returns

IPN NMX PharmaceuticalsMX Market
7D0%-1.9%1.0%
1Yn/a-11.9%2.5%

Return vs Industry: Insufficient data to determine how IPN N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how IPN N performed against the MX Market.

Price Volatility

Is IPN N's price volatile compared to industry and market?
IPN N volatility
IPN N Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement4.2%
10% most volatile stocks in MX Market5.8%
10% least volatile stocks in MX Market2.7%

Stable Share Price: IPN N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine IPN N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19295,325David Loewwww.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPN N fundamental statistics
Market capMex$177.15b
Earnings (TTM)Mex$11.86b
Revenue (TTM)Mex$63.54b

14.9x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPN N income statement (TTM)
Revenue€3.31b
Cost of Revenue€571.20m
Gross Profit€2.74b
Other Expenses€2.12b
Earnings€617.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Jul 25, 2024

Earnings per share (EPS)7.47
Gross Margin82.72%
Net Profit Margin18.66%
Debt/Equity Ratio9.6%

How did IPN N perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

16%

Payout Ratio